Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Crinetics Pharmaceuticals Inc CRNX

Healthcare Biotechnology
Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its Paltusotine, an investigational, oral somatostatin receptor type 2 (SST2) agonist, is in Phase 3 clinical development for acromegaly and Phase 2 clinical development for carcinoid... see more

Recent & Breaking News (NDAQ:CRNX)

Crinetics Pharmaceuticals Announces March 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire March 11, 2024

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

GlobeNewswire February 28, 2024

Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement

GlobeNewswire February 28, 2024

Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024

GlobeNewswire February 14, 2024

Crinetics Pharmaceuticals Announces February 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire February 12, 2024

Crinetics Pharmaceuticals Announces January 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire January 10, 2024

Crinetics Pharmaceuticals to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 3, 2024

Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome

GlobeNewswire December 18, 2023

Crinetics Pharmaceuticals Announces December 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire December 11, 2023

Crinetics Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewswire November 20, 2023

Crinetics Pharmaceuticals Announces November 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire November 10, 2023

Crinetics Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update

GlobeNewswire November 7, 2023

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire October 10, 2023

Crinetics Pharmaceuticals to Participate in the Cantor Global Healthcare Conference 2023

GlobeNewswire September 20, 2023

Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

GlobeNewswire September 12, 2023

Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock

GlobeNewswire September 11, 2023

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire September 11, 2023

Crinetics' Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-1 Study Evaluating Treatment of Patients with Acromegaly

GlobeNewswire September 10, 2023

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire August 10, 2023

Crinetics Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update

GlobeNewswire August 8, 2023